Clinical Frequency and Characteristics of Peripheral Neuropathy in Dermatomyositis
JAMA Dermatology · 18.11.2026
DOI: 10.1001/jamadermatol.2026.4739 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, online erschienen am 18.11.2026. Verfasst von Sarini Saksena und 8 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Importance The occurrence of peripheral neuropathy (PN) in dermatomyositis (DM) is poorly characterized.
Objective
To characterize the occurrence, clinical patterns, and electrophysiological features of PN in patients with DM. Design, Setting, and Participants This cohort study used data from a single academic center database of patients with DM who were enrolled between July 2008 and December 2025. Patients with PN were identified through medical record review of problem lists, encounter diagnoses, and clinical notes. PN diagnosis was established by clinical examination, nerve conduction study (NCS), or skin punch biopsy. Patients with PN that was associated with diabetes or prediabetes, vitamin deficiency, infection, trauma, nerve compression, radiculopathy, or neurotoxic medication were excluded. Exposures DM subtype, autoantibody positivity, and systemic manifestations. Main Outcomes and Measures Main outcomes were frequency and clinical/electrophysiological characteristics of PN among patients with DM.
Results
Among 640 patients with DM (median [IQR] age, 60 [40.8-70.0] years; 546 [85.3%] female; 94 [14.7%] male), 120 (18.8%) had clinically documented PN (median [IQR] age, 60 [50.5-70.8] years; 104 [86.7%] female; 16 [13.3%] male), ascertained at a median (IQR) of 3 (1-9) years after DM diagnosis. Patients with PN were significantly more likely to have classic DM than patients without PN (75 of 120 [62.5%] vs 269 of 520 [51.7%]; P = .03). Patients with PN had higher rates of arthralgia (95 of 120 [79.2%] vs 93 of 511 [18.2%]; P < .001) and Raynaud syndrome (67 of 120 [55.8%] vs 198 of 511 [38.7%]; P < .001), and lower myositis-specific antibody positivity (28 of 104 patients [26.9%] vs 112 of 295 [38.0%]; P = .04), than patients without PN. NCS was performed in 61 patients, with positive findings in 39 patients (63.9%) and negative findings in 22 patients (36.1%). Mixed sensory-motor polyneuropathy was most common (23 of 39 patients [58.9%]), followed by pure sensory neuropathy (12 of 39 patients [30.8%]), with axonal features predominating (37 of 39 patients [94.9%]) over demyelinating features (2 of 39 patients [5.1%]). Small-fiber neuropathy was biopsy-confirmed in 4 patients (3.3%) and clinically suspected without biopsy confirmation in 16 patients (13.3%). Conclusions/Relevance In this cohort study, clinically documented PN was identified in nearly one-fifth of the DM cohort after exclusion of secondary causes and was associated with classic DM subtype and higher rates of arthralgia and Raynaud syndrome. The predominance of axonal over demyelinating patterns on NCS suggests inflammatory axonal injury as one possible mechanism, though other causes cannot be excluded. These findings suggest PN is an underrecognized systemic association of DM warranting heightened clinical awareness and further mechanistic investigation.
Zitieren
APA
Saksena, S., Wei, E., Jun, S., Gross, N., Eldaboush, A., Gomes, L. L. A., Feng, R., Lancaster, E., & Werth, V. P. (2026). Clinical Frequency and Characteristics of Peripheral Neuropathy in Dermatomyositis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2026.4739
Vancouver
Saksena S, Wei E, Jun S, Gross N, Eldaboush A, Gomes LLA, et al. Clinical Frequency and Characteristics of Peripheral Neuropathy in Dermatomyositis. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2026.4739
BibTeX
@article{Saksena2026,
author = {Saksena, Sarini and Wei, Elena and Jun, Sarah and Gross, Naomi and Eldaboush, Ahmed and Gomes, Lais Lopes Almeida and Feng, Rui and Lancaster, Eric and Werth, Victoria P.},
title = {Clinical Frequency and Characteristics of Peripheral Neuropathy in Dermatomyositis},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2026.4739}
}
EUVIMED